New developments in biotechnologies designed to fight infections in lung diseases such as Cystic Fibrosis are showing positive advancements for patients with the disease. Pulmatrix Inc., a biotech company developing novel inhalation therapeutics using its proprietary iSPERSE™ (inhaled small particles easily respirable and emitted) technology, recently released data for its pre-clinical studies on the powdered formulation of the antibiotic levofloxacin, PUR0400, at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico.
Levofloxacin is a member of the fluoroquinolone class of antibiotics that offer protection from a wide range of both gram positive and gram negative bacterium responsible for urinary, respiratory and gastrointestinal tract infections. It is a bactericidal antibiotic which is responsible for inhibiting DNA replication and culminating into death of the bacterium.
The iSPERSE™ formulation is a novel technique taking nebulization to a new level. It promises to deliver drugs in a fine dry powder form instead of the usual misty liquid form, and ensure proper and efficient dispersion within the lungs because of its unique formulation. This makes the drug more effective. This technology can be used for any drug and all possible combination of drugs as well, as per the demand.
PUR0400 is one of several iSPERSE antibiotic formulations targeted towards respiratory disorders like cystic fibrosis (CF) and non-CF bronchiectasis. This form of the antibiotic has been shown to possess the desirable aerosol properties and can be stored successfully under given conditions which makes it more robust and gives an edge over its competitors.
Commenting on the potential of PUR0400 Robert Clarke, PhD , Chief Executive Officer of Pulmatrix said, “The development of PUR0400 marks a significant step for the company in advancing multiple iSPERSE programs towards clinical testing. These data significantly advance our understanding of our novel platform technology and highlight our ability to formulate high drug load products in a format that avoids liquid nebulization and is convenient to patients.”
Adding to this, David Hava, PhD, Chief Scientific Officer of Pulmatrix, commented, “The PUR0400 data highlight an advantage of the iSPERSE technology over conventional dry powder technologies in the stable formulation of high drug loads for lung delivery. Together with a robust preclinical data package using a number of different antibiotics, these data provide the support for continued development of inhaled antibiotic formulations in a number of respiratory diseases.”
With the need for innovative technologies and drug formulations for diseases such as Cystic Fibrosis increasing by the day, especially in the field of antimicrobials, the iSPERSE technology comes as a boon to the pharmaceutical industry. Provided further trials yeild positive results, this technology could provide major profits to the pharma industry, though putting patient satisfaction as the foremost priority.
MRSA is a serious threat to CF patients. Get more information about [adrotate banner=”75″].